Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
-
Leuven, Belgio, 3000
- UZ Leuven
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montréal, Quebec, Canada, H3A 2B4
- Montreal Neurological Institute Clinical Research Unit
-
-
-
-
Hérault
-
Montpellier, Hérault, Francia, 34295
- Hopital Gui de Chauliac, Service de Neurologie
-
-
Paris
-
Paris cedex 13, Paris, Francia, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Berlin, Germania, 13125
- Charité - Campus Virchow-Klinikum
-
Hannover, Germania, 30625
- Medizinische Hochschule Hannover
-
Jena, Germania, 07743
- Universitaetsklinikum Jena
-
Ulm, Germania, 89081
- Universitaetsklinikum Ulm
-
-
-
-
-
Dublin, Irlanda, Dublin 9
- Beaumont Hospital
-
-
-
-
CX
-
Utrecht, CX, Olanda, 3584
- UMC Utrecht
-
-
-
-
West Midlands
-
Sheffield, West Midlands, Regno Unito, S102JF
- Royal Hallamshire Hospital
-
-
-
-
California
-
San Diego, California, Stati Uniti, 92103
- University of California San Diego Medical Center
-
San Francisco, California, Stati Uniti, 94115
- California Pacific Medical Center
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- University of South Florida
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- The Emory Clinic
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Charlestown, Massachusetts, Stati Uniti, 2129
- Massachusetts General Hospital, MA
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stati Uniti, EC037
- Penn State Milton S. Hershey Medical Center
-
-
-
-
-
St. Gallen, Svizzera, 9007
- Kantonsspital St. Gallen
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Key Inclusion Criteria:
- A diagnosis of sporadic or familial ALS
- ALS onset within ≤5 years
- Must be 16 to 85 years of age, inclusive, for sites in the United States and 18 to 85 years of age, inclusive, for all sites outside of the United States
Key Exclusion Criteria:
- History of or positive test result at Screening for human immunodeficiency virus (HIV)
- History of or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (HBV)
- Possibility of neuromuscular weakness other than ALS
- Unspecified reasons that, in the opinion of the site Investigator, make the subject unsuitable for enrollment or unlikely to be able to complete, at a minimum, the Month 6 Visit
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
EIM is an electrophysiological technique in which current is applied to a muscle of interest and resultant voltage and impedance are measured.
These measured parameters reflect the conductivity of underlying tissue and presumably the pathologic state of denervated muscle in an ALS participant
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
CMAP is a standard electrophysiological measure generated by maximally stimulating a nerve such that all muscle fibers innervated by the respective nerve are depolarized.
Reduction of CMAP amplitude reflects loss of motor axons and, therefore, is directly relevant to ALS.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
Optional, to be administered at each site's Investigator's discretion.
MUNE is used to estimate the number of functioning motor units.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
MUNIX estimates functioning motor units within a muscle.
CMAP and surface electromyography potentials (surface interference patterns) are obtained at various levels of voluntary effort, and MUNIX is estimated using power and area of CMAP and surface interference patterns.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
HHD tests isometric strength of multiple muscles using standard participant positioning.
Approximately 10 muscle groups will be examined (per each side) in both upper and lower extremities.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
Vital capacity will be measured by means of an SVC test, administered in the upright position.
Upright SVC will be determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Lasso di tempo: Baseline to Month 6 and Baseline to Month 12
|
The ALSFRS-R has been demonstrated to predict survival.
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills.
There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 [Cedarbaum 1999], with higher scores representing better function.
|
Baseline to Month 6 and Baseline to Month 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for CMAP
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNE
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNIX
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for HHD
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for SVC
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R
Lasso di tempo: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival
Lasso di tempo: Baseline to Month 24
|
Baseline to Month 24
|
|
Comparison between 6-month changes for muscle electrophysiological measures
Lasso di tempo: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for muscle strength measures
Lasso di tempo: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for functional measures
Lasso di tempo: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison of molecular biomarkers with disease progression
Lasso di tempo: Baseline to Month 12
|
Baseline to Month 12
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 999AS003
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .